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Abstract
In 2007 an estimated 33 million people were living with HIV; 67% resided in sub-Saharan Africa, with 35% in eight
countries alone. In 2007, there were about 1.4 million HIV-positive tuberculosis cases. Globally, approximately 4 mil-
lion people had been given highly active antiretroviral therapy (HAART) by the end of 2008, but in 2007, an esti-
mated 6.7 million were still in need of HAART and 2.7 million more became infected with HIV.
Although there has been unprecedented investment in confronting HIV/AIDS - the Joint United Nations Pro-
gramme on HIV/AIDS estimates $13.8 billion was spent in 2008 - a key challenge is how to address the HIV/AIDS
epidemic given limited and potentially shrinking resources. Economic disparities may further exacerbate human
rights issues and widen the increasingly divergent approaches to HIV prevention, care and treatment.
HIV transmission only occurs from people with HIV, and viral load is the single greatest risk factor for all modes of
transmission. HAART can lower viral load to nearly undetectable levels. Prevention of mother to child transmission
offers proof of the concept of HAART interrupting transmission, and observational studies and previous modelling
work support using HAART for prevention. Although knowing one’s HIV status is key for prevention efforts, it is not
known with certainty when to start HAART.
Building on previous modelling work, we used an HIV/AIDS epidemic of South African intensity to explore the
impact of testing all adults annually and starting persons on HAART immediately after they are diagnosed as HIV
positive. This theoretical strategy would reduce annual HIV incidence and mortality to less than one case per 1000
people within 10 years and it would reduce the prevalence of HIV to less than 1% within 50 years. To explore
HAART as a prevention strategy, we recommend further discussions to explore human rights and ethical considera-
tions, clarify research priorities and review feasibility and acceptability issues.
Introduction
T h et r a j e c t o r yo ft h eb e g i n n i n go ft h em o d e r ne r ao f
public health can be traced from Jenner’s inoculation of
James Phipps in England in 1796 to the last case of wild
smallpox in Somalia in 1977. This is not to suggest that
the focus of this commentary is the eradication of HIV,
but rather that HIV is a virus and that we should visua-
lize, as Thomas Jefferson did when he wrote to Jenner
in 1806 that “future generations will know by history
only that this loathsome disease has existed”.J e f f e r s o n
did not know that it would take 170 years before this
would take place, but as the principal author of the
Declaration of Independence, he was very familiar with
hubris and taking the long view. Highly active
antiretroviral treatment (HAART) may prove to be one
of the combination prevention interventions that can
help us to realize our collective goal of relegating HIV
to the history books.
It is important to pause and consider the devastating
extent of the HIV pandemic. In 2007, an estimated 33
million people were living with HIV [1]. About 68%
reside in sub-Saharan Africa, with 35% in eight coun-
tries alone [1]. HIV is the strongest risk factor for tuber-
culosis (TB), and in 2008, there were about 1.4 million
HIV-positive TB cases, representing 15% of global TB
incidence [2]. About 26% of global TB deaths were esti-
mated to be HIV associated, and 23% of HIV deaths
were likely from tuberculosis [2]. In 2005, representa-
tives of the G8 countries met in Scotland and com-
mitted to achieving universal access to HIV prevention,
care and treatment by 2010 [1]. More recently, the G8
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access remains a dream for millions of people and faces
serious technical, economic and political challenges on a
number of fronts [1].
Although there has been unprecedented investment in
confronting HIV/AIDS - the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) estimates $13.8 billion
was spent in 2008 [3] - one of the key challenges facing us
is not only how to sustain, but also to expand our
response to the HIV/AIDS epidemic. This challenge is
compounded by the fact that we are now facing the worst
economic crisis since the 1930s. The magnitude and com-
plexities of the economic problem are at times beyond
comprehension. For example, the US lost more than
460,000 jobs in June 2009 alone and has already borrowed
a trillion dollars. Many US states are nearly bankrupt and
some have begun issuing paper credits in lieu of tax
returns and salaries. The ripple effects of the US economic
meltdown are being felt worldwide and is impacting
investment in international and national public health.
We have made significant progress in meeting Univer-
sal Access objectives, and by the end 2008, there were 4
million people on HAART, almost 73% in Africa;
285,000 children were on HAART, a 45% increase since
2007 [4]. This is an extraordinary achievement that has
required an unprecedented partnership of many stake-
holders, combined with innovative approaches to
resource mobilization. The expansion of access to
HAART faced considerable skepticism by experts and
others, who posited that treatment for HIV could not be
delivered to impoverished countries in Africa and else-
where. Service delivery for millions of people living with
HIV is achieved one patient at a time and involves
remarkable efforts by health care workers and people
living with HIV and their families.
Discussion
The prevention gap
Despite these gains, there is an urgent need for both
increased investment and more efficient use of available
funding. Although 4 million people were on treatment
by the end of 2008, by the end of 2007, 6.7 million
needed treatment and in 2007, there were 2.7 million
new infections. Around 23 million people were waiting,
mostly unknowingly, to become treatment eligible,
sicken or die. Although the additional 1 million people
added on treatment in 2008 is impressive, with 2.7 mil-
lion new infections in 2007, the treatment gap, which
estimates the number of people with HIV eligible for
HAART against those with access to HAART, only
decreased from 95% to 69% by the end of 2007 [1]. We
will need to dramatically reduce HIV incidence to keep
pace with demand, with universal access appearing
increasingly remote.
More troubling yet is the fact that these coverage per-
centage estimations are based on eligibility for HAART
of CD4 counts of less than 200 cells/mm
3, and will likely
be revised downward to reflect starting treatment at
higher CD4 thresholds. The Economist raised these con-
cerns regarding the significant prevention and treatment
gap: “As a result, taxpayers are accumulating an indefi-
nite - and indefinitely growing - responsibility for keeping
people alive. Somehow, somebody has to work out how
to stop the disease spreading.” [5] This economic per-
spective clearly emphasizes that as we expand treatment
without decreasing HIV transmission, it will become pro-
gressively more difficult to cover the increasing costs.
Human rights-based approach is essential
The HIV epidemic has raised issues of equity and human
rights in ways that other public health threats may not
have received similar attention. A human rights-based
approach to building a strong public health response to
HIV/AIDS is essential. It is widely recognized by public
health experts and others that coercion and other manda-
tory approaches to addressing the HIV epidemic often
have perverse negative outcomes. Although challenging,
programmes that engage the community as a meaningful
partner in the design and implementation have a greater
chance of success, particularly when the potential for
stigma and human rights violations exists [6]. There is
increasing concern that the existing stark economic dispa-
rities will further exacerbate human rights issues and
widen the increasingly divergent approaches to HIV pre-
vention, care and treatment that are seen between rich
and poor countries [7,8].
Re-examining our current approach to controlling HIV
More than 27 years after the discovery of the HIV [9],
control of the HIV epidemic remains elusive, and there
have been calls to re-examine the current approach to
controlling HIV. Given the clear HIV prevention gap,
we must collectively find solutions to one of the most
pressing public health problems facing us: how do we
interrupt HIV transmission and drive the epidemic into
the ground? Combination prevention includes a broad
systemic analysis and tailored response that includes evi-
dence-based interventions to address behavioural
change, HAART, other biomedical strategies, and struc-
t u r a ls o c i a lj u s t i c ea n dh u m an rights interventions
[10,11]. The rest of the article will focus on biomedical
prevention interventions, but we need to keep in mind
the importance of using our entire evidence-based
arsenal in a combined prevention approach.
Biomedical interventions
Research on biomedical interventions to interrupt sexual
transmission have been disappointing, although there
have been some signs of hope. Of 26 randomized con-
trolled trials of different interventions, including four
vaccine, 10 microbicide and three herpes suppression
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tive trials included three on male circumcision, and the
sexually transmitted infection intervention trial in
Mwanza, Tanzania, more than a decade ago, of limited
generalizability [14].
At the Conference on Retroviruses and Opportunistic
Infections (CROI 2009) in Montreal, Canada, in Febru-
ary 2009, Karim and colleagues presented results from
HPTN 035 assessing the microbicide gel, Pro 2000 [15].
Though not reaching statistical significance, a 30%
reduction in HIV incidence was observed in gel users.
Pre-exposure prophylaxis (PrEP) can be provided
through topical, as well as oral antiretroviral agents [15].
Encouraging animal data suggest that a HAART-con-
taining gel may provide pre-exposure protection [16].
The efficacy of oral PrEP is being assessed in 10 ongoing
or planned randomized controlled trials involving some
20,000 participants internationally; the first results are
expected in late 2009 or 2010. Although PrEP is promis-
ing, it may take unusual persuasiveness to convince a
decision maker to give drugs to HIV-uninfected persons
when many with declared HIV disease are dying from
lack of access.
Recent results from the vaccine trial in Thailand [17]
remind us that while implementing evidence-based,
near-term prevention solutions, work must continue to
develop a vaccine that could be used in the future to
mitigate the HIV epidemic. The overall situation has
prompted many people to consider the potential preven-
tion role of HAART.
Scientific evidence for HAART as prevention
Before considering the potential impact of HAART for
prevention, it is important to consider the scientific evi-
d e n c ef o rt h eb a s i ca s s u m p t i o n sb e h i n dH A A R Tf o r
prevention. These assumptions include the obvious but
often overlooked fact that HIV transmission occurs only
from people with HIV [9].
There are studies supporting the assumption that viral
load is the single greatest risk factor for all modes of
transmission. Quinn’s landmark study in Rakai, Uganda,
showed that patients with less than 400 copies of HIV
RNA per millilitre. have the lowest rate of HIV trans-
mission, and demonstrated a stepwise increase in trans-
mission rates for higher RNA levels [18]. Lowering viral
load is essential to interrupting transmission, and
HAART can lower viral load to nearly undetectable
levels. A 2009 meta-analysis that included 11 cohorts
and 5021 heterosexual couples concluded that there was
zero risk of sexual transmission while on HAART for
those with HIV-1 RNA below 400 copies with an upper
confidence limit of 1.27 per 100 years [19].
Prevention of mother to child transmission (PMTCT)
offers proof of the concept of HAART interrupting
HIV transmission. Although some would argue that
lessons from PMTCT may not be applicable to pre-
venting sexual transmission, perinatal AIDS cases have
been virtually eliminated in the United States [20].
This is likely due to the implementation of Public
Health Service guidelines for the universal counselling,
voluntary HIV testing and HAART for pregnant
women and newborn infants [20]. Recent trial data
from sub-Saharan Africa support HAART to block
PMTCT, with one study showing a decrease of trans-
mission to 1% [21].
Observational studies illustrate the potential for
HAART for prevention of HIV transmission [22]; Bun-
nell and colleagues in Uganda showed that when
HAART is added to couples counselling, transmission
during sex can be reduced by 98% [23]. Numerous stu-
dies suggest a potential for the community-level impact
of HAART on HIV transmission. In British Columbia,
public health scientists showed a decrease in community
plasma HIV RNA concentrations and HIV incidence
among injecting drug users associated with HAART use
[24]. Work from Taiwan found a 53% reduction in new
HIV cases associated with the provision of free access to
HAART [25]. Additional data from areas with high anti-
retroviral treatment (ART) coverage do exist, and addi-
tional community-based studies examining the impact
of HAART on HIV transmission are in preparation.
When to start?
Although knowing one’s HIV status is key for preven-
tion, it is not known with certainty how early to start
HAART. People living with HIV in sub-Saharan Africa
start HAART at a median CD4 count of around 100
cell/mm
3, which is much later than in the north [26].
This lack of access to HAART until very late in the
course of the disease is decreasing in areas as people
learn their HIV status earlier, guidelines change and ser-
vices expand. However, mortality is still markedly higher
in sub-Saharan Africa compared with other contexts
[26,27].
At CROI 2009, Lawn and colleagues from South
Africa showed a steeply increasing risk of death in
patients on HAART associated with the time spent
below 200 CD4+ cells/mm
3 [28,29]. Mortality reached
almost 40/100 person years when the CD4+ count was
less than 50 [28,29]. Although mortality rates at the
higher CD4 levels may be relatively low, when applied
to large numbers of people living with HIV, this lower
risk converts into a significant impact on mortality.
Observational data from North American cohorts
showed that among 8362 patients with a CD4+ count of
351 to 500 cells/mm
3, deferral of therapy until the CD4
+ count had fallen to 350 cells/mm
3 or less was asso-
ciated with an increase of 69% in the risk of death, as
compared with patients who initiated therapy when
their CD4+ count was within the designated range
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confidence interval [CI], 1.26 to 2.26; P < 0.001) [30].
Similarly, among 9155 patients with a CD4+ count of
more than 500 cells/mm
3, deferral of therapy until the
CD4+ count fell below 500 cells was associated with a
significantly increased risk of death of 94% (relative risk,
1.94; 95% CI, 1.37 to 2.79; P < 0.001) [30,31]. Although
not a randomized clinical trial and relying on relatively
few events, it nevertheless presents further evidence for
the potential benefits of starting earlier and is in line
with other observational data [26]. Sax and Baden, in
their accompanying editorial, suggest that we may be
moving to an era when most people will choose to start
HAART when they are ready [31]. The When to Start
Consortium analyzed data from 18 cohorts in Europe
and North America and included more than 40,000
patients [26]. Starting treatment at higher CD4 counts
reduced the probability of AIDS or death, with those
starting before reaching a level of 450 cells/mm
3 having
the most benefit [26]. There are numerous other cohort
studies that also suggest that starting earlier is better
[32-34].
Trial data, although limited, also point in the direction
of an earlier start. The National Institutes of Health-
supported randomized clinical trial, CIPRA HT 001, in
Haiti was stopped by the Data Safety Monitoring Board.
Patients who started treatment earlier, with CD4 counts
of between 200 and 350 cells/mm
3, had significantly
fewer deaths and fewer cases of TB compared with
those who had deferred treatment to less than 200 cells/
mm
3 or when an AIDS-defining illness occurred.
ACTG A 1564, conducted predominantly in the Uni-
ted States, compared early with deferred HAART in
patients treated for various opportunistic events (but
not TB) [35]. Survival curves show a 47% reduced pro-
gression or death in patients receiving immediate as
opposed to deferred HAART [35]. There is increasing
evidence that suggests the damaging effects of HIV,
even at higher CD4 count levels [36,37]. The SMART
trial showed not only that starting earlier provided
superior outcomes; it also suggested that HIV may be
associated with serious non-AIDS-defining events,
including cardiovascular, renal and liver disease and
non-AIDS malignancies [36,37]. For some, this evidence
of HIV infection as a chronic inflammatory disease pro-
cess provides additional rationale for an earlier start of
HAART.
TB is the major killer for most people living with HIV
in sub-Saharan Africa. Studies from Cape Town demon-
strate increasing TB incidence, and the group has coined
the phrase, “TB death zone”, to describe living below
500 cells/mm
3 [28,29]. There is increasing recognition
among people working on HIV-related TB that HAART
has a significant role to play in preventing TB morbidity,
transmission and mortality. Preliminary results of the
South African SAPIT trial, presented at CROI 2009,
compared outcome of HAART integrated with TB treat-
ment versus deferred treatment until TB therapy was
completed in patients with CD4+ counts below 500
cells/mm
3 [15]. There was a 56% reduction in mortality
in the integrated group, and this applied across the
whole CD4+ spectrum in a stratified analysis [15].
The emerging evidence suggests that HAART should
be initiated as soon as possible in acute illness. The evi-
dence increasingly suggests that if the future is to be dif-
ferent, we have to intervene with treatment far earlier,
before people living with HIV fall into or spend too
long in the CD4+ “death zone” for tuberculosis.
Under universal access, most people living with HIV
will eventually become eligible and require HAART.
How early to start HAART is a matter of perspective,
and the crux of the issue is time from HIV infection. A
recent study gathered CD4 and RNA data from 30 inter-
national studies and 16 cohorts of untreated adults with
HIV [38]. The analysis of median CD4 counts over time
found relatively low starting levels and a relatively rapid
progression to commonly discussed CD4 thresholds,
such as 500, 350 and 200 [38].
The time to reach commonly used CD4 eligibility
thresholds for HAART was variable and in some set-
tings, only a few years after HIV infection [38]. Data
suggests that on average it takes about two to four years
to reach a CD4 count of 500 cells/mm
3, depending on
one’s starting point; from this perspective this represents
a significant amount of time. However, if we consider
that people will live for tens of years on HAART, then
the two to four years it would take to reach a CD4 level
of 500 cells/mm
3 makes up only a small fraction of the
remaining years of life. In other words, optimally most
people will have access to HAART, and when discussing
whether to start at 200, 350 or 500, we are really dis-
cussing the difference of a few years earlier in the course
of a much longer life span on HAART.
Guidelines are written for the context within which
they are meant to be applied, and European, North
America and World Health Organization (WHO)
recommendations are divergent on a number of impor-
tant issues. In addition to clear differences in formulary
and laboratory support, in countries with more
resources, people are started earlier, and factors, such as
viral replication status, CD4 decline and being in a dis-
cordant couple, are now appearing as potential start cri-
teria, even at higher CD4 counts.
Consideration of the durability of currently used regi-
mens in resource-constrained settings will be central in
evaluating using HAART for prevention. Our ongoing
scientific and moral challenge will be to continue to
narrow the treatment gulf between north and south and
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two standards of care: one for the richer countries and
the other for the poorer, for lack of better terms.
Essentially all people living with HIV will eventually
require HAART for clinically progressive, ultimately
fatal immunodeficiency. Regardless of when we decide
that people should start HAART, we will not reach uni-
versal access to prevention, care and treatment unless
millions of people with HIV learn their HIV status.
Despite considerable efforts to expand access to HIV
testing, an estimated 80% of people living with HIV in
sub-Saharan Africa do not know their status and 90%
do not know their partners’ status [1].
Kenya is a leader in improving access for HIV coun-
selling and testing. However, data from the 2007 Kenya
AIDS Indicator Survey shows that of people eligible for
HAART (with a CD4 count of less than 250), 57% have
no idea that they have HIV [39]. Knowing one’sH I V
status was a key determinant in accessing treatment in
Kenya: 92% of those who knew their status and were eli-
gible were on HAART [39]. Susan Allen, working in the
late 1980s and ‘90s in Rwanda and Zambia, and many
others have built the scientific evidence base to show
that HIV counselling and testing itself [23,40,41], parti-
cularly when it involves couples counselling, can be a
remarkably effective prevention intervention [23,41,42].
Community-based efforts, including home-based cou-
ples counselling and testing, have considerable promise.
Through a seven-day campaign designed to prevent
HIV, diarrheal disease and malaria in a district in wes-
tern Kenya, a private sector company working with local
non-governmental organizations, Centers for Disease
Control Kenya, and the Ministry of Health was able to
test 41,040 or 80% of the men and women between 15
and 49. The total population reached was 47,311, out of
which 97% were voluntarily tested and counselled for
HIV. Of those reached, 18,300 or 38% were men [43].
Of course, knowing one’s HIV status is not enough:
the cornerstones of HIV counselling and testing scale
up must include improved protection from stigma and
discrimination, as well as improved access to integrated
prevention, treatment and care services. A human rights
approach, based on the “3C s ” of HIV testing (confiden-
tiality, counselling and informed consent) is a prerequi-
site for success [44].
Modelling results
This quote from George Box, one of the most influential
statisticians of the last century, puts it nicely: “Essen-
tially, all models are wrong, but some are useful.” Mod-
els help us to better understand what we think we know
and perhaps most importantly, what we need to find
out. Our model [45] builds on and extends earlier ana-
lyses suggesting that rapid scale up of conventional
HAART approaches could significantly reduce mortality
[46] and have a substantial impact on HIV incidence
[47,48].
R0 or reproductive ratio is the average number of sec-
ondary cases of infection to which one primary case
gives rise throughout its infectious period. We focused
on a generalized HIV epidemic setting largely driven by
h e t e r o s e x u a ls e x ,a n du s e dd a t af r o mS o u t hA f r i c a ,
Uganda, Malawi and elsewhere [45]. The South Africa
HIV surveillance data shows an initial doubling time of
1.25 years, which means that on average each person
with HIV infects another person once every 1.25 years.
Life expectancy for people with HIV was 10 years,
which allows us to estimate an R0 of around 7. There-
fore, we assumed that cutting transmission by a factor
of more than 8 would reduce R0 < 1 and eliminate HIV
infection.
We used a stochastic model for estimating R0 and we
examined phases and relative infectivity with time. The
parameter values for infectivity are not known precisely,
but we used the calculated R0 and the literature for our
assumptions. The relative importance of the acute phase
and concurrency has been the subject of some debate
among modellers, epidemiologist and others. We con-
ducted sensitivity analyses by varying the degree of
infectiousness and the duration of the acute, chronic
and final phases [45].
We used a stochastic model to examine the frequency
of HIV testing and CD4 level needed to get R0 <1 .W e
would need to test people on average about once per
year and need to start them on immediate HAART
when their CD4 count was around 1000. In the South
African setting, the average CD4 count after conversion
is 884. Therefore to reach R0 < 1 for most people, we
need to start HAART immediately, irrespective of CD4
count. We also see that annual testing and a CD4
threshold of 200 gives you a R0 of 4 - a significant
reduction in transmission but not elimination, which we
defined as 1000 cases per million per year [45].
For the model, we used the 2007 estimate that 5% of
people living with HIV were already on HAART and
that programme coverage increases logistically. In other
words, programme coverage reaches 50% in 2012 and
90% in 2016 [45]. The model’s programme start date
can be altered accordingly, with more rapid implementa-
tion translating into shortened time to maximal impact.
We added in a 40% prevention effect whereby transmis-
sion would be additionally decreased by 40% over the
time period. For some, this is optimistic for a combined
prevention approach, and for others, not high enough,
but we felt that if current prevention efforts beyond
HAART could decrease transmission by 40%, that
would be reasonable.
Although this combined approach dramatically
reduces transmission, it does mean that a large cohort
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course, we thought that this was not a bad thing since
they would at least be alive, and it is similar to acceler-
ated universal access, but nevertheless represents a sig-
nificant challenge. Modelling showed that the universal
voluntary HIV testing and immediate HAART strategy
with combined prevention interventions resulted in a
95% reduction in incidence or new HIV cases in 10
years. The theoretical strategy reduced incidence from
15-20,000 per million population to 1000 per million
and the prevalence to less than 1% by 2050 [45].
The model suggests that mortality would decline
rapidly and the epidemic would become concentrated
with particular populations remaining at risk. Health
services could then switch focus from making HAART
available to those in greatest need to providing support
and services for those who are on HAART. While
other prevention interventions, alone or in combina-
tion, could significantly reduce HIV incidence, the
model suggests that only universal HIV testing and
immediate initiation of HAART could reduce transmis-
sion to the point where elimination might be feasible
by 2020 for a generalized epidemic, such as that in
South Africa. The less than 350 strategy has a major
impact, but we are left with a persistent epidemic. In
summary, the universal voluntary HIV testing and
immediate treatment strategy drives down incidence,
prevalence and mortality towards an elimination
phase [45].
The different strategies do come with different
impacts: the less than 350 on HAART strategy could
save nearly 2.41 million lives, while the universal
voluntary HIV testing combined prevention approach
nearly triples that number to 7.35 million [45]. These
dramatic results beg the question: how much will it
cost? We did a rough costing for the strategies based
on the estimated costs of delivering ART [45]. The
funding needed to implement the theoretical strategy
for an epidemic of South African-type severity peaks in
2015 at $3.4 billion per year (range: $2.2 billion-$5.3
billion).
Although the initial yearly cost of the theoretical strat-
egy is higher than the present strategy, it is within
UNAIDS projections of the $8.84 billion needed every
year for universal access to prevention, care, and treat-
ment in a South African-type situation in 2015 [45].
The “front-loaded” universal voluntary strategy is initi-
ally more expensive, but becomes cost saving around
2030 as the HIV epidemic moves toward elimination
[45]. A programme of this size would require consider-
able initial effort. However, over time, the decreasing
HIV incidence would free scarce health care resources
that are currently overwhelmed by the immediate
demands of the HIV epidemic.
Next steps
The theoretical strategy of universal voluntary HIV and
immediate HAART raises a new set of challenges and,
as with all prevention interventions for HIV, this
approach should not be viewed independently of other
methods of prevention [49]. The strategy assumes rela-
tively rapid programme expansion, high adherence, and
significant community acceptance and participation.
Expert evaluation and further research and discussion is
required to assess this novel approach, its appropriate-
ness and its feasibility, and to define the requirements
for public health decision making on how to best use of
HAART for prevention and control of HIV/AIDS.
We are engaged in further modelling on other impor-
tant aspects, such as the impact of HAART on TB, the
relative importance of drug resistance and other
assumptions, the impact of PrEP, effects on PMTCT,
and an in-depth economic analysis of the various strate-
gies. Preliminary results are very interesting and we look
forward to sharing them soon.
We hope that this work has helped key stakeholders
to consider the potential role of HAART as part of com-
bined HIV prevention efforts. In early November 2009,
WHO held two meetings to discuss HAART for preven-
tion [50]. As part of WHO’sc o n v e n i n gr o l e ,s t a k e -
holders were invited to explore human rights and
ethical considerations, clarify research priorities and
review feasibility and acceptability issues (the presenta-
tions, selected articles, list of participants and outcomes
of the meeting are available at http://www.who.int/hiv/
topics/artforprevention/.
Conclusions
The model has raised many questions for all of us. We
are reminded of this quote by Hermann Biggs, a pioneer
in United States public health: “Public health is purcha-
sable. Within a few natural and important limitations
any community can determine its own health.”
Unlike the weather, HIV is an infectious disease and
can be controlled and possibly even eliminated: it will
be up to us to work together to make that happen using
the many tools that we have developed over the past 27
y e a r s .A l t h o u g hH A A R T ,c o n d o m s ,c o u p l e sc o u n s e l l i n g
and a future vaccine are critical tools, their true public
h e a l t hi m p a c tc a no n l yb ea c h i e v e dw h e nw eu s eo u r
common purpose and ability to reason to address one of
the toughest public health problems facing our global
community.
Disclaimer
The opinions and statements in this article are those of
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